Phase 2/3 trial of maintenance lapatinib for HER1/2-positive metastatic bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma.

Share this video